Navigation Links
Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
Date:4/15/2008

-No Metastatic Lesions Were Detectable After Combination Therapy Treatment-

-Survival Time More Than Doubled in Animals Treated with Combination

Therapy- -Established Tumors Regressed by 50% After Combination Therapy Treatment-

SAN DIEGO and TUSTIN, Calif., April 15 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that preclinical data presented at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) shows that a mouse equivalent of Peregrine's anti-phosphatidylserine (anti-PS) vascular targeting antibody bavituximab administered in combination with the chemotherapeutic agent docetaxel demonstrated excellent signs of efficacy in a preclinical model of hormone-refractory prostate cancer. These new data confirm and extend the results of previous studies of Peregrine's anti-PS antibodies in models of prostate cancer. They were described by researchers in an oral presentation at the AACR Annual Meeting at 2:10pm PDT on April 14, 2008 in San Diego, California.

Dr. Yi Yin, a postdoctoral researcher in the laboratory of Dr. Philip Thorpe, professor of pharmacology at the University of Texas Southwestern Medical Center at Dallas, reported that in a mouse model of hormone-refractory prostate cancer, the combination of the bavituximab equivalent antibody 2aG4 and the chemotherapy drug docetaxel significantly decreased the growth of tumors, eliminated detectable metastases and prevented tumor re-growth. This increase in anti-tumor efficacy and anti-metastatic activity was achieved w
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
2. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
3. PG500 Series Presented at the AACR Annual Meeting in San Diego
4. Research Presented at ISHLT Shows Promise of Addressing Critical Organ Shortage and Better Organ Preservation
5. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
6. Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings
7. Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
8. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
9. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
10. New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ
11. New Clinical Studies Presented at the 14th World Congress of Anesthesiology Demonstrate Masimo Advancements in Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...  Express Scripts Holding Company (Nasdaq: ESRX ... Express Scripts stockholders of $515.2 million, or $0.67 per ... in Table 4, was $1.23 for the second quarter. ... serve our clients with scale, alignment and innovative solutions to ... outcomes of our members," stated George Paz, chairman and chief ...
(Date:7/29/2014)... , July 29, 2014  EnteroMedics Inc. (NASDAQ: ... using neuroblocking technology to treat obesity, metabolic diseases and ... a conference call on Thursday, August 7, 2014 at ... the second quarter ended June 30, 2014 and to ... The second quarter conference call may be ...
(Date:7/29/2014)... New high priced hepatitis C drugs will increase federal ... to $5.8 billion next year, according to a new ... the Pharmaceutical Care Management Association (PCMA). Milliman projects that ... as 8.6 percent in 2015 as a result of ... The study finds that the majority of new ...
Breaking Medicine Technology:Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 8Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 9Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 10Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 11Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 12Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 13Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 14Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 15Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 16Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 17Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 18Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 19Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 20Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 21Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 22Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 23Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 24Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 26Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 27Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 28Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 29Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 30Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 31EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2
... July 14, 2011 Regulus Therapeutics Inc ., ... innovative medicines targeting microRNAs, today announced that it has ... (SAB). The addition of Dr. Hannon, a researcher whose ... the microRNA pathway, increases SAB membership to six pioneers ...
... FRAZER, Pa., July 14, 2011 Cephalon, Inc. (Nasdaq: ... approve the Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA ... cash, or a total enterprise value of approximately $6.8 billion. ... Federal Trade Commission and the European Commission.  Cephalon and Teva ...
Cached Medicine Technology:Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 2Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 3Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 4Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 5Cephalon Shareholders Approve Acquisition by Teva 2
(Date:7/29/2014)... July 30, 2014 Recent international ... devices have determined Nurse Call Systems to be ... this requires all Nurse Call Systems to be ... improves patient safety, reduces clinical risks, and is ... based Corporate Risk and Clinical Risk Committee actively ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Daily Gossip ... the program was actually created by a popular nutritionist ... He tried numerous treatments for this disorder, but none ... himself in the situation of having to look for ... of research. Dawson used this method, too, to become ...
(Date:7/29/2014)... Advertising claims for cosmetic procedures using stem cells are ... and effectiveness, according to a review in the August ... , the official medical journal of the American ... offer tremendous potential, but the marketplace is saturated with ... at risk," write Dr Michael T. Longaker of Stanford ...
(Date:7/29/2014)... According to a July 22, 2014 report ... Kim’s Butt to Angelina’s Lips: The Plastic Surgery Procedures ... celebrity feature most requested by women seeking cosmetic surgery. ... Jennifer Lawrence’s nose, and Angelina Jolie’s ... collected by an online community focused on plastic surgery ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Tylenol ... individuals who allegedly suffered serious liver injuries due ... move forward in a multidistrict litigation underway in ... Liebhard LLP reports. According to an Order dated ... deadlines pertaining to bellwether case and discovery issues. ...
Breaking Medicine News(10 mins):Health News:NiQ Health Reveals the Extensive Use of Unregulated Medical Devices in Australian Hospitals 2Health News:NiQ Health Reveals the Extensive Use of Unregulated Medical Devices in Australian Hospitals 3Health News:NiQ Health Reveals the Extensive Use of Unregulated Medical Devices in Australian Hospitals 4Health News:Natural Vitiligo Treatment System Review Reveals Michael Dawson’s New Vitiligo Cure Program 2Health News:Beware of claims about cosmetic stem cells procedures, says review in Plastic and Reconstructive Surgery 2Health News:Celebrity Plastic Surgery: Kim Kardashian’s Butt Tops the List of Celebrity Plastic Surgery Requests 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 4
... can positively affect the human brain function, according to ... research, which was published in the journal NeuroImage ... environment impacts upon our brain functions. The ... such as the sea, cause distinct brain areas to ...
... 10 to 12 years younger than their white counterparts, according ... Neurology , the medical journal of the American Academy of ... the basis of 20 years of data, is among the ... disparities in health care, say Dr. Nicte Mejia and Dr. ...
... used to treat attention-deficit/hyperactivity disorder (ADHD) also provides ... that affect many childhood cancer survivors, according to ... Research Hospital investigators. Researchers reported that one ... survivors scored better on tests of sustained attention ...
... By Amanda Gardner HealthDay Reporter , MONDAY, ... Administration will ask an expert panel later this week whether ... to suspected heart risks. In documents released Monday ahead ... that members of its Endocrinologic & Metabolic Drugs Advisory Committee ...
... tests of mental aging reveals a good news-bad news situation. ... with age, to varying degrees. The good news is the ... to a study published by the American Psychological Association. ... and what,s called crystallized intelligence decline at older ages," said ...
... in which cells restrain beta-catenin and potentially suppress tumor ... small vesicles called exosomes. The study appears online on ... ( www.jcb.org ). Beta-catenin is a central ... proliferation and differentiation. Activation of the Wnt pathway stabilizes ...
Cached Medicine News:Health News:Study shows tranquil scenes have positive impact on brain 2Health News:Blacks with muscular dystrophy die 10-12 years younger than whites: New study 2Health News:Childhood cancer survivors show sustained benefit from common ADHD medication 2Health News:Childhood cancer survivors show sustained benefit from common ADHD medication 3Health News:FDA Panel to Mull Ban on Diet Drug Meridia 2Health News:FDA Panel to Mull Ban on Diet Drug Meridia 3Health News:New study reconciles conflicting data on mental aging 2Health News:New study reconciles conflicting data on mental aging 3Health News:Exosomal release of beta-catenin may explain why CD82 and CD9 suppress tumor metastasis 2
This design features a solid red iris....
This pattern transform your pupils into narrow slits surrounded by eye stopping yellow. Works well with kitty-cat costumes....
This camouflaging lens features the solid black stripes of the lightning fast African zebra, on a white iris background....
Silicone tip cannula angled at 7 mm, sterile, disposable (bx/10)....
Medicine Products: